A regenerative approach to Alzheimer’s treatment, with Dr. Joshua Hare

While a lot of work in Alzheimer’s is focused on the amyloid cascade hypothesis, it’s not the only one. And recent research published in Nature Medicine suggests that a neuro-inflammation hypothesis can also lead to promising results in treating the condition.

At Longeveron, Dr. Joshua Hare and his team are working on an Alzheimer’s treatment using human-derived bone marrow mesenchymal stem cells. In this interview from the sidelines of BIO 2025, Editor in Chief Jonah Comstock caught up with Hare to learn more about his recent findings.

They also discuss the FDA’s RMAT designation for streamlined approval of regenerative medicine and, more generally, early indications of the priorities of the new administration at the FDA, following Hare’s attendance of their recent symposium.

Check out the full video below.